Stock info Galectin Therapeutics Inc | Filter  Basic-Info

Galectin Therapeutics Inc

The past year gave good returns for Galectin Therapeutics Inc investors

Over the last 12 months, that were loss-making period for the investors in Galectin Therapeutics Inc, the stock lost around 50 percent. The period between August 2011 and August 2016 was a loss-making period for the investors. The stock lost on average 83 percent. Galectin Therapeutics Inc's net incomes between 2011 and 2015 were very volatile and moved between -10,92 million dollars and -20,03 million dollars.

Galectin Therapeutics Inc is active in the biotech sector. The global biotech companies gained around 59 percent over the last 10 years. Measured since 2011 the sector is 70 percent higher and over the past 12 months (December 2015-December 2016) there is a minus of 59 percent.

Galectin Therapeutics Inc didn't pay out any dividends (in the past 5 years).

Galectin Therapeutics Inc's balance mostly financed with debt

Last year the balance sheet of the American company was worth 26,41 million dollars. The total debt was around 1,36 million dollars. This is 5,15 percent of the total balance sheet. The American company's price/earnings-ratio was -4. So the market valued the stock at -4 times the 2015' earnings per share. We could say that based on it's price/earnings-ratio and dividend yield the American stock can be seen as a value stock.

At the end of 2015 the biotech company's market capitalization (the number of shares times the market price) equaled around 40,52 million dollars. At the end of 2015 the American company had around 24,12 million stocks listed.

All the company's financial reports are available here. More information about Galectin Therapeutics Inc can be found it's website. .